

7:00 am – 4:00 pm ACMT Pre-Symposium Registration / Information  
Regency Foyer/West Tower  
Ballroom Level

7:00 am – 8:00 am Continental Breakfast  
Regency Foyer/West Tower  
Ballroom Level

8:00 am – 4:00 pm **ACMT Pre-Symposium: Performance and Enhancing**  
**Agents 360**  
Regency Ballroom ABC  
West Tower  
Ballroom Level  
**Moderators: Jerrold Leikin, MD**  
**Heather Long, MD**  
**Daniel Sessions, MD**

***Presentations:***

***Athletic Performance Enhancing Drug Use in Society***  
***Christopher Hoyte, MD***

***Analytical Testing for Performance Enhancing Drugs***  
***Daniel Sessions, MD***

***Management of Positive Tests for Performance Enhancing***  
***Drugs: The Process for U.S. Military Personnel***  
***Joseph Maddry, MD***

***\*\*Doping and the Law\*\****  
***Timothy Liam Epstein, ESQ.***

***\*\*I'm Not in the Business of Failing: Perspective of the***  
***High Performer\*\****  
***Brian Bardsley, EMT-P***

***Panel: Different Perspectives on Drug Testing &***  
***Compliance***  
***Moderator: Christopher Hoyte, MD***

**Bold Face** – indicates CE sessions

\* Restricted to committee members \*

\*\* Presentation will not be audio recorded\*\*

***Performance Enhancement Panel Discussion: Do the Ends Justify the Means?***

***Panelists:***

***Jolie Holschen, MD***

***George Chiampas, DO***

***Timothy Liam Epstein, JD***

***Joseph Maddry, MD***

***Brian Bardsley, EMT-P***

***Daniel Sessions, MD***

***\*\*Providing Care for High Performance & Elite Athletes: the Sports Medicine Physician's Perspective on Performance Enhancing Drugs\*\****

***Jolie Holschen, MD***

***Building an Action Hero: Performance Enhancing Supplement Use in U.S. Service Members***

***Colonel Melissa (Missy) Givens***

***\*\*Forensics Case Studies: Performance Enhancing Drugs as Contributing Factors in Sudden Death in Athletes\*\****

***Jolie Holschen, MD***

***Veterinary Issues in Performance Enhancing Agents***

***Stephen Schumacher, DVM***

***Building the Logistics of Drug Testing in Sport: Perspective of the Medical Director for Large Events***

***George Chiampas, DO***

***Risk and Reward: The Influence of Performance Enhancing Drugs on Amateurs and the General Population***

***Michael Marlin, MD***

At the end of this session, the participant should be able to:

1. Identify common athletic performance enhancing drugs used by all people in society.
2. Discuss the toxicity of these agents.
3. Describe how performance enhancing drug testing in military personnel is executed and reported.
4. Contrast the Role of a Medical Review Officer (MRO) in the military to an occupational MRO.
5. Discuss Medical Review Officer's role in handling of positive PED test results in US military personnel.
6. Describe administrative action necessary after a positive PED test result in US military personnel.
7. Understand the historical perspective from counsel on the legality/constitutionality of drug testing.
8. Discuss the perspective of counsel defending the rights of a high performer who tests positive.
9. Explain the perspective of law enforcement and other professionals on performance standards.
10. Discuss issues with both performance achievement and long term maintenance for individual professionals.
11. Discuss the role of the physician in educating athletes about the use of banned or harmful over-the-counter substances or prescription medications.
12. Review the drug testing rules and regulations affecting the treatment of illness/injury in athletes, including threshold use, in and out-of-competition, & TUEs.
13. Describe patterns of performance enhancing supplement use in U.S. Service members.
14. Understand nuances of performance enhancement in U.S service members compared to athletes as it pertains to supplement use.
15. Examine the role of performance enhancing drugs, diet, exercise, and nutritional supplements on sudden death in athletes through several case studies.
16. Implement preventative education programs to athletes and coaches and provide physician oversight of exercise regimens.
17. Identify and understand the challenges in regulating the use of medications in sport horses as compared to human athletes.
18. Identify the differences in regulating race horses as compared to sport horses.
19. Understand the processes and procedures of drug and doping testing in elite Athletes.
20. Build greater awareness on steps taken to educate athletes on performance enhancing drugs, avoidance and management.

**Bold Face** – indicates CE sessions

Page 3 of 45

\* Restricted to committee members \*

\*\* Presentation will not be audio recorded\*\*

21. Become familiar with current abuse trends of specific PEDs in the general population, including emerging drugs of abuse.
22. Understand the unique risks and adverse effects of PED use in the general population compared to elite athletes and high performers.

8:00 am – 5:00 pm           \*AACT Board Meeting\*

Toronto

West Tower/ Ballroom Level

12:00 pm – 6:00 pm       \*ABAT Exam\* (Part 1)

Acapulco

West Tower/Ballroom Level

5:00 pm – 9:00 pm       \*ABAT Board Meeting\* (Part 1)

Hong Kong

West Tower/Ballroom Level



***History of Methamphetamine***  
***Frank LoVecchio, DO, MPH***

***The Cathinones***  
***David Wood, MD***

***Synthetic Cannabinoids***  
***Janetta Iwanicki, MD***

***MDMA, Molly, NBOme***  
***Daniel E. Rusyniak, MD***

***Novel Psychoactive Drugs***  
***Elizabeth Moore, DO***

***Natural Products of Abuse***  
***William Eggleston, PharmD***

***\*\* The Evolution of Drug Trafficking in the United States\*\****  
***Cori Rizman, DEA Diversion Investigator/Press Officer***

***Opioids***  
***Jeanmarie Perrone, MD***

At the end of this session, the participant should be able to:

1. Describe the history of LSD use.
2. Describe the pharmacology of LSD.
3. Describe the pharmacology and toxicology of older sedatives such as barbiturates, glutethimide, ethchlorvynol, and others.
4. Describe how the pharmacodynamic effects of barbiturates differ from those of benzodiazepines.
5. Understand how history and social circumstance affected cannabinoid research, use, and legislation.
6. Understand how initial regulatory and legislative actions influenced current trends in cannabinoid use and abuse.
7. Compare and contrast the physiologic effects of cocaine with those of thyrotoxicosis and pheochromocytoma.

**Bold Face** – indicates CE sessions

\* Restricted to committee members \*

\*\* Presentation will not be audio recorded\*\*

8. Describe the theoretical reasons why beta blockade would be unwise in acute cocaine toxicity.
9. Assess the evidence base in support and against the use of beta blockers in acute cocaine toxicity.
10. Develop an evidence based treatment strategy for patients with acute cocaine toxicity.
11. Describe the historical role adulterants have played in illicit drug use.
12. Describe the pathophysiology of select adulterants.
13. Appreciate the history of phencyclidine use and abuse.
14. Understand phencyclidine's various pharmacologic actions and clinical manifestations.
15. Describe different methods of inhalant abuse.
16. Differentiate acute and chronic inhalant toxicity.
17. Understand unique toxicities associated with specific inhalants.
18. Discuss the History of Methamphetamine.
19. Discuss signs and symptoms of Methamphetamine toxicity.
20. Understand the history of the cathinone group of novel psychoactive substances.
21. Describe the acute toxicity related to the recreational use of cathinones.
22. Identify common presenting symptoms in patients with synthetic cannabinoid toxicity.
23. Identify common treatments for symptomatic patients with synthetic cannabinoid toxicity.
24. Discuss the mechanism of MDMA-mediated hyperthermia.
25. Discuss the environmental contributors to MDMA-mediated toxicity.
26. Identify clinical toxicity associated with novel psychoactive drugs of abuse.
27. Review the history and development of novel psychoactive drugs.
28. Discuss the history and legal status of ayahuasca, ibogaine, and kratom in the United States and Canada
29. Describe the clinical manifestations of ayahuasca, ibogaine, and kratom abuse.
30. Understand how drug trends have changed over time and the ways in which they are infiltrated into the supply chain (both legitimate and rogue).
31. Provide an overview and historical perspective of the opioid crisis on a national level.
32. Describe the rationale for judicious opioid use.

8:00 am – 1:00 pm                      \*ABAT Exam\* (Part 2)

Acapulco

West Tower/Ballroom Level

**Bold Face** – indicates CE sessions

\* Restricted to committee members \*

\*\* Presentation will not be audio recorded\*\*

8:00 am – 5:00 pm           \*ACMT Board Meeting\*  
Stetson E  
West Tower/Exhibit Level

8:00 am – 5:00 pm           \*ABAT Board Meeting\* (Part 2)  
Hong Kong  
West Tower/Ballroom Level

12:00 pm – 5:00 pm         \*AAPCC Board Meeting\* (Part 1)  
Toronto  
West Tower/Ballroom Level

1:00 pm – 6:00 pm           NACCT Conference Registration / Information  
Regency Foyer/West Tower  
Ballroom Level

1:00 pm – 5:00 pm           Exhibitor Set - Up  
Riverside West  
East Tower/Exhibit Level

1:00 pm – 5:00 pm           Poster Session I Set-Up - Abstracts # 17-106  
Riverside West  
East Tower/Exhibit Level

4:00 pm – 7:00 pm           AAPCC SPI Committee General Meeting  
Acapulco  
West Tower/Ballroom Level

5:00 pm – 10:00 pm         \* AAPCC Accreditation Meeting \*  
Atlanta  
West Tower/Ballroom Level

5:00 pm – 6:00 pm           AAPCC Benchmarking / QA Meeting  
Toronto  
West Tower/Ballroom Level

5:00 pm – 6:00 pm           PEC Open Meeting  
Michigan 2  
East Tower/Concourse Level

**Bold Face** – indicates CE sessions

\* Restricted to committee members \*

\*\* Presentation will not be audio recorded\*\*



5:00 pm – 6:00 pm            AAPCC Surveillance Team  
Stetson E  
West Tower/Exhibit Level

**5:00 pm – 7:00 pm            ACMT Medical Toxicology:  
Regency Ballroom ABC    *20th Annual Clinical Pathophysiology Competition (CPC)*  
West Tower                *Moderator: Jeffrey R. Suchard, MD*  
Ballroom Level**

At the end of the session, the participant should be able to:

1. Formulate an approach to the diagnosis of complex poisoning cases based on limited data.
2. Describe the management of several unique poisonings.
3. Identify potential pitfalls in the diagnostic approach to poisoned patients.

6:00 pm – 7:00 pm            PEC Steering Committee Meeting  
Roosevelt 1AB  
East Tower/Concourse Level

6:00 pm – 7:00 pm            AAPCC Truven Joint Coding Committee Meeting  
Toronto  
West Tower/Ballroom Level

6:30 pm – 8:00 pm            CAPCC Business Meeting  
Stetson E  
West Tower/Exhibit Level

7:00 pm- 9:00pm            AAPCC SPI Meet & Greet Reception  
Hong Kong  
West Tower/Ballroom Level

**Bold Face** – indicates CE sessions

\* Restricted to committee members \*

\*\* Presentation will not be audio recorded\*\*

7:00 pm -9:00 pm

Offsite

Lou Malnati's Pizzeria

PEC Meet and Greet

7:00 pm – 8:00 pm

Plaza Ballroom A

East Tower

Lobby Level

AACT Business & Membership Meeting

8:00 pm – 9:00 pm

Plaza Ballroom B

East Tower

Lobby Level

AACT Members' Reception and FAACT Induction Ceremony

*Moderator: Robert Palmer PhD, AACT President*

**Bold Face** – indicates CE sessions

\* Restricted to committee members \*

\*\* Presentation will not be audio recorded\*\*

7:00 am – 6:00 pm            NACCT Main Congress Registration / Information  
Regency Foyer/West Tower  
Ballroom Level

7:00 am – 8:30 am            Continental Breakfast:  
Regency Foyer/                *Sponsored by Johnson & Johnson Consumer, Inc.*  
West Tower/Ballroom Level

7:30 am – 8:30 am            AACT Envenomation Section  
Atlanta  
West Tower/Ballroom Level

7:30 am – 8:30 am            AAPCC Managing Directors  
Toronto  
West Tower/Ballroom Level

7:30 am – 8:30 am            ACMT Quality Measures Workgroup  
Stetson F  
West Tower/Exhibit Level

7:30 am – 8:30 am            ACMT Women in Tox Section  
Roosevelt 1B  
East Tower/Concourse Level

7:30 am – 8:30 am            ACMT Position Statements and Guidelines  
Roosevelt 3A  
East Tower/Concourse Level

7:30 am – 8:30 am            AACT Acute and Intensive Care Section  
Stetson D  
West Tower/Exhibit Level

7:30 am – 8:30 am            AACT Herbs and Dietary Supplements Section  
Stetson G  
West Tower/Exhibit Level

7:30 am – 8:30 am            AACT Pediatric Section  
Stetson E  
West Tower/Exhibit Level

**Bold Face** – indicates CE sessions

\* Restricted to committee members \*

\*\* Presentation will not be audio recorded\*\*

7:30 am – 8:30 am            AACT WMD Section  
 New Orleans  
 West Tower/Ballroom Level

**8:30 am – 9:30 am            NACCT Keynote Presentation:**  
**Regency Ballroom            *\*\*Organized Crime in Chicago During Prohibition\*\****  
**West Tower                      *Moderator: Mark Kostic, MD***  
**Ballroom Level                *Presenter: John J. Binder, PhD***

At the end of the session, the participant should be able to:

1. Discuss the history of organized crime in Chicago and how certain toxic substances, such as illegal narcotics or tainted alcohol, fit in this history.

**9:00 am – 4:00 pm            Exhibits/Posters Session I-Abstracts # 17-106**  
**Riverside West**  
**East Tower/Exhibit Level**

**9:30 am – 10:30 am            Executive Directors Evaluation Committee**  
**Roosevelt 1B/ East Tower/ Concourse Level**

**9:30 am – 10:30 am            Authors with Posters - Abstracts # 17-106**  
**Riverside West                Refreshment Break**  
**East Tower/Exhibit Level**

**10:30 am – 11:30 am            EAPCCT Scientific Symposium: Toxin Induced Organ**  
**Regency Ballroom AB            *Failure***  
**West Tower                      *Moderator: Bruno Mégarbane, MD, PhD***

***Presenters:***  
***Is there a place for non-invasive mechanical ventilation and high-flow nasal cannulae to treat drug-induced respiratory failure?***  
***Raido Paasma, MD, PhD***

***Are new vasopressors and inotropic drugs useful to treat drug-related cardiovascular failure?***  
***Florian Eyer, MD***

**Bold Face** – indicates CE sessions

\* Restricted to committee members \*

\*\* Presentation will not be audio recorded\*\*

***ECMO to treat acute poisonings: indications and results***  
***Bruno Mégarbane, MD, PhD***

At the end of the session, the participant should be able to:

1. Discuss about use of non-invasive ventilation in case of acute poisoning.
2. Compare CPAP ventilation and high-flow nasal oxygen therapy.
3. Acknowledge benefits and risks of classic vasopressors and more recent inotropes in the management of toxin-induced cardiovascular failure.
4. Describe the role of levosimendan in the treatment of cardiovascular failure induced by toxins.
5. To identify the best indications for veno-arterial ECMO in acute poisonings.
6. To know how to monitor the poisoned patient treated with veno-arterial ECMO.

**10:30 am – 11:30 am**  
**Regency Ballroom C**  
**West Tower**  
**Ballroom Level**

**ACMT Practice Symposium: God and Man at the Bar-**  
***Addiction, Sobriety and Spirituality***  
***Moderator: Gerald O'Malley, DO***

***Presenters:***  
***Gerald O'Malley, DO***  
***Rachel Haroz, MD***

At the end of the session, the participant should be able to:

1. Describe the methods by which addicts from different religious and cultural backgrounds access spirituality to achieve and maintain sobriety.
2. Describe the relative importance and influence of spirituality in the approach to drug and alcohol addiction and rehabilitation.

**10:30 am – 11:30 am**  
**Toronto**  
**West Tower**  
**Ballroom Level**

**PEC: Health Literacy: Best Practices for Effective**  
***Educational Messages***  
***Moderator: Laura Morehouse, CHES***

***Presenter: Michael S. Wolf, PhD***

**Bold Face** – indicates CE sessions

\* Restricted to committee members \*

\*\* Presentation will not be audio recorded\*\*

At the end of the session, the participant should be able to:

1. Identify 3 health system targets for health literacy interventions and how each impact patient engagement and outcomes.
2. Provide 2 examples of how clinical workflows can be modified to accommodate better patient-provider communication.

**11:30 am - 12:30 pm**      **AACT Tox History Section: *The Past 50 Years***  
**Regency Ballroom AB**      **Moderator: *Anna Arroyo Plasencia, MD***  
**West Tower**  
**Ballroom Level**      **Presenters: *Howard McKinney, PharmD***  
    ***Mark Winter, PhD***

At the end of the session, the participant should be able to:

1. Review the history of AACT.
2. Review a selection of the people in and accomplishments of AACT.

**11:30 am – 12:15 pm**      **Lightning Oral Abstracts: # 28, 29, 30, 119, 191**  
**Regency Ballroom C**      ***Moderator: Mark Ryan, PharmD***  
**West Tower**  
**Ballroom Level**

**# 28 *Impact of Legislation Legalizing Recreational Marijuana Sales on Cannabis Exposure Calls to Poison Centers 2008-2017*, Gillian Beauchamp, MD**

**# 29 *Clinical Prediction Rule for Torsade de Pointes in Patients with Drug-Induced QT Prolongation*, Rittirak Othong, MD**

**# 30 *A Comparison of Resource Utilization and Adverse Events Related to the Management of Anticholinergic Delirium between Physostigmine and Non-Antidote Therapy*, Sean Boley, MD**

**# 119 *Five years of Physo: a Retrospective Review of the Safety and Efficacy of Physostigmine Use at an Academic Tertiary Care Hospital*, Rachel Gorodetsky, PharmD**

**# 191 *Dose-Dependent Pulmonary Injury Following Kinepak Exposure*, David Perez Lauterbach, MD**

**Bold Face** – indicates CE sessions

Page 14 of 45

\* Restricted to committee members \*

\*\* Presentation will not be audio recorded\*\*

At the end of the session, the participant should be able to:

1. State the age range and sex of cases most commonly reported to poison centers for cannabis exposure between 2008-2017.
2. State whether states with legalized recreational cannabis had an increase or decrease in cannabis-related calls to poison centers.
3. Identify risk factors and patients at risk for drug induced torsade de pointes.
4. Better understand the effectiveness of physostigmine as well as its effect on resource utilization and development of adverse events.
5. Describe the most common exposures for which physostigmine was used in this case series.
6. Discuss the incidence of adverse effects to physostigmine in this case series.
7. Recognize nitrogen dioxide related lung injury in uncommon presentations.

**11:30 am – 12:30 pm**  
**Regency Ballroom D**  
**West Tower**  
**Ballroom Level**

**ABAT Scientific Symposium: From Toxicologist to Entrepreneur: The Basics for Starting a Consulting Business**  
**Moderators: Alfred Aleguas Jr., PharmD**  
**Howard McKinney, PharmD**

**Presenter: Allison Muller, BS Pharm, PharmD**

At the end of the session, the participant should be able to:

1. Identify 2 skills needed to start a consulting business.
2. List 2 niche areas of consulting for toxicologists.

**11:30 am – 12:30 pm**  
**Toronto**  
**West Tower**  
**Ballroom Level**

**PEC: Health Information Seeking in the Digital Age**  
**Moderator: Stefanie Baines, CHES**

**Presenter: Alexis Lauricella, PhD**

At the end of the session, the participant should be able to:

1. Discuss the different avenues through which health information can be obtained - Internet, Family and/or Friend, Health care professionals, Traditional media (Books, brochures, magazines, and library).
2. Discuss how different audiences (adolescents/teens and adults/parents) access and use health information.

**Bold Face** – indicates CE sessions

\* Restricted to committee members \*

\*\* Presentation will not be audio recorded\*\*

**Saturday, October 27, 2018 (continued)**

**Conference Schedule**

12:30 pm – 1:30 pm      \*Tox Collaborative AC Project\*  
Atlanta  
West Tower/Ballroom Level

12:30 pm – 1:30 pm      \*JMT Editorial Board Meeting\*  
Roosevelt 1B  
East Tower/Concourse Level

12:30 pm – 2:00 pm      \*AHLS Board Meeting\*  
New Orleans  
West Tower/Ballroom Level

12:30 pm – 1:30 pm      Lunch on Your Own

12:30 pm – 2:00 pm      \*RADARS Canadian Poison Centre's\*  
Acapulco  
West Tower/Ballroom Level

12:30 pm – 1:30 pm      ACMT Military Section  
Roosevelt 3A  
East Tower/Concourse Level

12:30 pm – 1:30 pm      ACMT ToxIC Network  
Roosevelt 3B  
East Tower/Concourse Level

12:30 pm – 1:30 pm      AACT Geriatric Section  
Stetson G  
West Tower/Exhibit Level

12:30 pm – 1:30 pm      AACT Radiation Section  
Stetson E  
West Tower/Exhibit Level

**Saturday, October 27, 2018 (continued)**

**Conference Schedule**

12:00 pm – 1:30 pm      \*AACT Clinical Toxicology Editorial Board Meeting\*  
Stetson F

**Bold Face** – indicates CE sessions

\* Restricted to committee members \*

\*\* Presentation will not be audio recorded\*\*



West Tower/Exhibit Level

1:30 pm – 3:30 pm      **Platform Session I: Abstracts # 1-8**  
Regency Ballroom AB      **Moderators: Darren Roberts, MD, PhD**  
West Tower                      **Mark Ryan, PharmD**  
Ballroom Level

**#1 Montelukast and Risk of Neuropsychiatric Events in Children with Asthma: a Population-based, Nested Case-control Study, Prof. Yaron Finkelstein, MD**

**#2 The Changing Face of Acute Liver Failure in the Wake of the US Prescription Opioid Epidemic: Review of 327 Cases of Acetaminophen- Induced Acute Liver Failure over 12 years, Lydia Baltarowich, MD**

**#3 Acetaminophen-Protein Adducts Following Acetaminophen Overdose, Angela Chiew, MD**

**#4 Money Talks for Medical Tox: Financial Impact of the Medical Toxicology Specialty Code on a Private Practice, Jerrold Leiken, MD**

**\*\* #5 Changing Nomogram Risk Zone Classification with Serial Testing following Acute Acetaminophen Overdose, Marco Silvotti, MD\*\***

**#6 Meeting the Demand for Naloxone: Stability of Expired Naloxone Solution, Heather Long, MD**

**#7 Acetaminophen Metabolites following Acute Acetaminophen Overdose as a Biomarker for Acute Liver Injury, Angela Chiew, MD**

**#8 The Effects of Activated Charcoal (AC) and Polyethylene Glycol Electrolyte Solution (PEG-ELS) on Bupropion XL Concentration in Vitro, Morgan Riggan, MD**

At the end of the session, the participant should be able to:

1. Appreciate the risk of neuropsychiatric events in children with asthma administered montelukast compared to other asthma maintenance medications.
2. Understand how the prescription opioid epidemic contributed to the rising number of acetaminophen- induced acute liver failure cases and mortality.

**Saturday, October 27, 2018 (continued)                      Conference Schedule**

3. Know the factors that were likely to be associated with the development of acetaminophen- induced acute liver failure and death in this study.

**Bold Face** – indicates CE sessions

Page 17 of 45

\* Restricted to committee members \*

\*\* Presentation will not be audio recorded\*\*

4. To understand how the use of acetaminophen-protein adducts may help predict which patients will develop hepatotoxicity following acetaminophen overdose.
5. Understand Metrics of CMS reimbursement.
6. Understand the financial impact of the CMS based physician specialty codes on a Medical Toxicology Practice.
7. Appreciate the frequency and implications of “line-crossing” following acetaminophen overdose.
8. Better appreciate the need for serial testing following acetaminophen overdose.
9. Understand the public interest surrounding the quality and stability of expired Naloxone HCl Solutions for Injection.
10. Suggest further investigations to confirm the findings of the current study.
11. Understand how acetaminophen metabolites in acute acetaminophen overdose may be used as a possible biomarker to predict acute liver injury.
12. Understand the relationship between activated charcoal, polyethylene-glycol with electrolyte solution and bupropion.

3:30 pm – 3:45 pm  
Regency Foyer &  
Riverside West

Refreshment Break  
*Sponsored by BTG International Inc.*

**3:45 pm – 4:45 pm**  
**Toronto**  
**West Tower**  
**Ballroom Level**

**PEC: AAPCC (American Association of Poison Control Centers) Updates**  
***Moderator: Stefanie Baines, CHES***

***Presenter: Court Squires, Pending Masters of Org. Dynamics***

At the end of the session, the participant should be able to:

1. We will address changes made to the AAPCC Public Education and Communications Department, as well as pending projects and possible partnerships.

**Saturday, October 27, 2018 (continued)**

**Conference Schedule**

**3:45 pm – 4:45 pm**  
**Regency Ballroom AB**

**AACT Radiation Special Interest Section Symposium:**  
**Radiation in Children and Pregnancy – Important Updates**

**Bold Face** – indicates CE sessions

Page 18 of 45

\* Restricted to committee members \*

\*\* Presentation will not be audio recorded\*\*

**West Tower  
Ballroom Level**

***for Clinical Toxicologists  
Moderator: Ziad Kazzi, MD***

***Presenters: Ziad Kazzi, MD  
Stephen Borron, MD  
Jennifer Lowry, MD***

At the end of the session the participant should be able to:

1. Discuss the developmental effects of radiation on the fetus.
2. Discuss the cancer risk after exposure to radiation in utero.
3. Discuss the non-cancer health effects from radiation exposure in children.
4. Discuss the cancer health effects from radiation exposure in children.
5. Discuss the epidemiology of radiation exposures and implications to health.
6. List sources of radiation exposure in children and pregnant women.

**3:45 pm – 4:45 pm  
Regency Ballroom C  
West Tower  
Ballroom Level**

**AACT Herbal Special Interest Section Symposium:  
*Herbal Alternatives for Opioid Dependency, Kratom and  
Ibogaine*  
Moderator: Michael Hodgman, MD**

***Presenters:  
Update on the Pharmacology and Legal Status of Kratom  
Walter C. Prozialeck, PhD***

***\*\*Ibogaine – Opioid Withdrawal\*\*  
Luke Yip, MD***

At the end of the session the participant should be able to:

1. Describe sources, uses, side effects and toxicities of kratom and kratom-derived drugs such as mitragynine and 7 hydroxymitragynine.
2. Discuss legal issues and controversies regarding use of kratom and kratom- derived drugs.
3. Review the history of ibogaine.
4. Review the pharmacology of ibogaine.
5. Review safety and clinical data on ibogaine in the treatment of opioid withdrawal.

**Saturday, October 27, 2018 (continued)**

**Conference Schedule**

**3:45 pm – 4:45 pm      SPI Roundtable**

**Bold Face** – indicates CE sessions

\* Restricted to committee members \*

\*\* Presentation will not be audio recorded\*\*

Page 19 of 45

Regency Ballroom D  
West Tower  
Ballroom Level

**Moderator: Randy Badillo, RN**

**Presenters: Denese Britt, MS, BSN  
George Bachman, BS Pharm**

**Panelists: Prashant Joshi, MD  
Scott Schaeffer, BS Pharm**

At the end of the session the participant should be able to:

1. Determine the appropriate course of treatment in an Acute Arsenic ingestion.
2. Identify the appropriate lab tests needed for evaluation of Arsenic toxicity.
3. Assess pertinent clinical symptoms and findings to determine treatment plan.
4. Ability to monitor plan to provide optimal outcome.

4:00 pm – 4:30 pm  
Riverside West  
East Tower/Exhibit Level

Posters Session I Tear Down – Abstracts # 17-106

4:45 pm – 5:45 pm  
Regency Ballroom C  
West Tower  
Ballroom Level

**\*\*ACMT Fellows- in -Training RoundTable: The Role Of  
Medico-Legal Consulting In Your Medical Toxicology  
Career\*\***

**Moderator: Christina Hantsch, MD**

**Presenters: Jeffrey Brent, MD, PhD  
Kavita Babu, MD  
Lewis Nelson, MD**

At the end of the session the participant should be able to:

1. Understand the role of medical-legal consultations in medical toxicology.
2. Understand the importance of medical toxicologists in medical-legal consultations.

**Saturday, October 27, 2018 (continued)**

**Conference Schedule**

4:45 pm – 5:45 pm  
Regency Ballroom D

**\*\*Updates from the Clinical Toxicology Recommendation  
Collaborative\*\***

**Bold Face** – indicates CE sessions

Page 20 of 45

\* Restricted to committee members \*

\*\* Presentation will not be audio recorded\*\*

**West Tower  
Ballroom Level**

**Moderator: Sophie Gosselin, MD**

**Presenters: Sophie Gosselin, MD  
David Wood, MD  
Greene Shepherd, PharmD  
Ingrid Berling, MD  
Rittirak Othong, MD**

At the end of the session the participant should be able to:

1. Discuss the evidence available for decontamination with activated charcoal.
2. Understand the complexities of QT measurement.

5:00 pm – 5:45 pm

Riverside West

East Tower/Exhibit Level

Poster Session II Set Up - Abstracts # 107-198

5:00 pm – 6:30 pm

Regency Ballroom AB

West Tower

Ballroom Level

AAPCC Quiz Bowl, SPI Awards and Scientific Poster Awards

Awards Moderator: "AAPCC"

Quiz Bowl Moderator: Prashant Joshi, MD

6:30 pm – 7:30 pm

Crystal Ballroom

West Tower/Lobby Level

NACCT Opening Reception

7:30 pm – 8:30 pm

Toronto

West Tower/Ballroom Level

ABAT Business Meeting

8:30 pm – 9:30 pm

Acapulco

West Tower/Ballroom Level

ABAT Members' Reception

8:00 pm – 10:00 pm

Offsite

\* NACCT Sponsors and Friends Dinner \*

**Bold Face** – indicates CE sessions

\* Restricted to committee members \*

\*\* Presentation will not be audio recorded\*\*

7:00 am – 5:00 pm            NACCT Main Congress Registration / Information  
Regency Foyer  
West Tower/Ballroom Level

7:00 am – 8:30 am            Continental Breakfast  
Regency Foyer  
West Tower/Ballroom Level

7:00 am – 7:30 am            AACT History Section  
Randolph 1B  
East Tower/Concourse Level

7:30 am – 8:30 am            AACT Occupational and Environmental Section  
Randolph 1B  
East Tower/Concourse Level

7:30 am – 8:30 am            AAPCC ToxSentry Data Group  
Regency Ballroom D  
West Tower/Ballroom Level

7:30 am – 8:30 am            AAPCC Toxicall Users Group  
Toronto  
West Tower/Ballroom Level

7:30 am – 8:30 am            AACT Scientific Committee  
Atlanta  
West Tower/Ballroom Level

7:30 am – 8:30 am            ACMT ASM Planning Committee  
New Orleans  
West Tower/Ballroom Level

7:30 am – 8:30 am            ACMT International Committee  
Acapulco  
West Tower/ Ballroom Level

7:30 am – 8:30 am            ACMT Research Committee  
Crystal Ballroom B  
West Tower/Lobby Level

**Bold Face** – indicates CE sessions

\* Restricted to committee members \*

\*\* Presentation will not be audio recorded\*\*

7:30 am – 8:30 am            AACT Forensic Section  
Roosevelt 1B  
East Tower/Concourse Level

**8:30 am – 9:30 am            AACT Scientific Symposium: Unexplained Somatic  
Regency Ballroom AB        Complaints: Differential Diagnosis and Clinical Strategies  
West Tower                    for Toxicologists  
Ballroom Level                **Moderator: Kennon Heard, MD****

***Presenter: Joshua Straus, MD***

At the end of the session, the participant should be able to:

1. Identify and recognize other conditions that may complicate evaluation and treatment of acetaminophen toxicity.
2. Identify other treatment protocols used in acetaminophen toxicity.

**8:30 am – 9:30 am            PEC: Swap and Share  
Crystal Ballroom A         Moderator: Jared O'Connor, MS, MPH  
West Tower  
Lobby Level                    **Presenters: Jared O'Connor, MS, MPH****

At the end of the session, the participant should be able to:

1. Share information about innovative and creative programs.
2. Compare poison prevention materials from a variety of poison centers.

**8:30 am – 9:30 am            AAPCC SPI Clinical Practice Symposium:  
Regency Ballroom C        Navigating the Gray Areas of Acetaminophen Toxicity  
West Tower                    Moderator: Jamie Nisbet, RN  
Ballroom Level**

***Presenters: Mike Abesamis, MD  
Mark Yarema, MD***

**Bold Face** – indicates CE sessions

\* Restricted to committee members \*

\*\* Presentation will not be audio recorded\*\*

At the end of the session, the participant should be able to:

1. Identify and recognize other conditions that may complicate evaluation and treatment of acetaminophen toxicity.
2. Identify other treatment protocols used in acetaminophen toxicity.
3. Differentiate between different treatment courses and options for treating acetaminophen
4. Identify different scenarios in which treatment for acetaminophen toxicity should be initiated or discontinued.

9:00 am – 4:00 pm                      Exhibits/ Poster Session II - Abstracts #107-196  
Riverside West  
East Tower/Exhibit Level

9:30 am – 10:30 am                      Authors with Posters – Abstracts # 107-196  
Riverside West                              Refreshment Break  
East Tower/Exhibit Level

**10:30 am – 11:30 am**                      ***ACMT Scientific Symposium: Hypersensitivity Issues in***  
**Regency Ballroom AB**                      ***Occupational Exposures***  
**West Tower**                                      ***Moderator: Jerold Leiken, MD***  
**Ballroom Level**  
  
***Presenters: Andrew Scheman, MD***  
***Peter Orris, MD***

At the end of the session, the participant should be able to:

1. Know common presentations of allergic contact dermatitis.
2. Know appropriate measures to take to assist in the management of allergic contact dermatitis.
3. Identify some of the industrial causes of occupational asthma.
4. Identify the pathophysiology of occupational asthma.

**Bold Face** – indicates CE sessions

\* Restricted to committee members \*

\*\* Presentation will not be audio recorded\*\*



**10:30am – 11:30 am**      **PEC: The Data You Don't Know You Need**  
**Toronto**                      **(Including Qualitative Research)**  
**West Tower**                 **Moderator: Stefanie Baines, CHES**  
**Ballroom Level**

**Presenter: Krista Osterthaler, MPH**

At the end of the session, the participant should be able to:

1. Name and describe a limitation to NPDS data.
2. Discuss how to characterize data.

**10:30 am – 11:00 am**      **Lightning Oral Abstracts: # 42, 63, 118, 180**  
**Regency Ballroom D**      **Moderator: Jillian Theobald, MD, PhD**  
**West Tower**  
**Ballroom Level**

**# 42 B17: Not Just a Vitamin, Rachel Shively, MD**

**#63 Pharmacokinetics of Acetaminophen and Metabolites After Accidental Acute Overdose in a Neonate, Angela Chiew, FACEM**

**# 118 Pharmacogenomic analysis of a patient with severe hepatotoxicity and hemolysis after Acetaminophen overdose despite early N-Acetylcysteine therapy**  
*Laura Tortora, MD*

**# 180 A Case of Rattlesnake Venom-induced Platelet Inhibition Reversed by Crotalidae Polyvalent Immune Fab as Demonstrated by Thromboelastography,**  
*Erik Fisher, MD*

At the end of the session, the participant should be able to:

1. Understand the clinical presentation of amygdalin toxicity.
2. Determine appropriate management of amygdalin toxicity.
3. Describe the metabolism of acetaminophen in a neonate following an acute overdose.
4. Consider the role of pharmacogenomics in identifying patients at risk of developing hepatotoxicity after Acetaminophen overdose, despite NAC therapy.
5. Understand the parameters measured in standard thromboelastographs with platelet mapping.
6. Identify platelet abnormalities that may be seen on thromboelastography with platelet mapping after Crotalinae envenomation's.

**Bold Face** – indicates CE sessions

Page 25 of 45

\* Restricted to committee members \*

\*\* Presentation will not be audio recorded\*\*

**10:30 am – 11:30 am**  
**Regency Ballroom C**  
**West Tower**  
**Ballroom Level**

**AACT Forensics Special Interest Section Symposium:**  
***Witness for the Prosecution: Honing Your Toxicological***  
***Expertise as an Expert Witness***  
***Moderator: Rama Rao, MD***

***Presenter: Rama Rao, MD***  
***Panelists: Jeffrey Brent, MD, PhD***  
***Marcia Ratner, PhD***  
***Christopher Hoyte, MD***  
***Allison Muller, BS Pharm, PharmD***  
***Daniel Goldstein, MD***  
***Thomas Kurt, MD***

At the end of the session, the participant should be able to:

1. Learn the common mistakes in starting a practice as an expert witness.
2. Understand the best practices in maintaining a practice and avoiding conflicts.

**11:00 am – 12:00 pm**  
**Regency Ballroom D**  
**West Tower**  
**Ballroom Level**

**AAPCC Veterinary Symposium: What's the big "D"eal with**  
***Cholecalciferol Overdoses? Comparing Human and Animal***  
***Overdoses***  
***Moderator: Tina Wismer, DVM***

***Presenters: Laura Stern, DVM, DABVT***  
***Jan Scaglione, PharmD***

At the end of the session, the participant should be able to:

Describe the differences between cholecalciferol toxicosis and treatment between humans and animals.

Describe potential adverse events from human exposure to vitamin D rodenticides.

Examine calculations for determination of severity of exposure to vitamin D rodenticides.

**11:30 am – 12:00 pm**      **AACT Career Achievement Award Lectureship:**  
**Regency Ballroom AB**      ***Unsettled Science in Pediatric Environmental Toxicology***  
**West Tower**      ***Moderator: Robert Palmer, PhD***  
**Ballroom Level**  
  
***Presenter: Alan Woolf, MD, MPH***

At the end of the session, the participant should be able to:

1. Define the 'precautionary principle' in children.
2. Describe the nature of PFAS chemicals and their scope of use.

12:00 pm – 1:00 pm      Lunch on your Own

12:00 pm – 1:00 pm      *\*Tox Collaborative QT Project\**  
 Atlanta  
 West Tower/Ballroom Level

12:00 pm – 1:00 pm      *\*AAPCC Committee Chairs & Fatality Review Luncheon\**  
 Acapulco  
 West Tower/Ballroom Level

12:00 pm – 1:30 pm      AACT Clinical Toxicology Senior Editorial Board Meeting  
 New Orleans  
 West Tower/Exhibit Level

12:00 pm – 1:00 pm      *\*AACT Fellows- in-Training and Leaders Luncheon\**  
 Crystal Ballroom B  
 West Tower/Lobby Level

12:00 pm – 1:00 pm      ACMT Medical Toxicology Foundation Board Meeting  
 Randolph 1B  
 East Tower/Concourse Level

12:00 pm – 1:00 pm      ACMT Membership Committee  
 Roosevelt 1A  
 East Tower/Concourse Level

**Bold Face** – indicates CE sessions

\* Restricted to committee members \*

\*\* Presentation will not be audio recorded\*\*

12:00 pm – 1:00 pm  
Roosevelt 1B  
East Tower/Concourse Level  
ACMT Education Committee

1:00 pm – 2:00 pm  
Regency Ballroom AB  
West Tower  
Ballroom Level  
**Platform Session II: Abstracts #9-12**  
**Moderators: Mark Kostic, MD**  
**Martin Wilks, MD, PhD**

**9. Capillary blood clotting time in detecting Venom-Induced Consumption Coagulopathy (VICC), Anjana Silva, PhD**

**10. Phospholipase A2 (PLA2) as an early indicator of envenomation in elapid snakebites (ASP-27), Geoffrey Isbister, MD**

**11. Prevalence of hematologic toxicity from copperhead envenomation: An Observational Study, Brandon Willis, DO**

**12. Opioid Exposures Reported to the National Poison Data System: Is the Heroin Disaster Resolving? Dan Spyker, MD, PhD**

At the end of the session, the participant should be able to:

1. Compare the performance of capillary blood clotting time with 20 minute whole blood clotting test for detecting Venom-Induced Consumption Coagulopathy (VICC).
2. Understand the measurement of phospholipase activity.
3. Understand the importance of early diagnostic biomarkers in snake envenomation.
4. Describe the prevalence of hematologic toxicity from copperhead envenomation.
5. Distinguish prevalence of copperhead-associated hematologic toxicity in Virginia compared to other regions.
6. Appreciate the change over time in heroin exposures reported to NPDS.

**Bold Face** – indicates CE sessions

\* Restricted to committee members \*

\*\* Presentation will not be audio recorded\*\*

**1:00 pm – 2:00 pm**  
**Regency Ballroom C**  
**West Tower**  
**Ballroom Level**

**CAPCC Scientific Symposium: Canadian Toxicological Epidemics**  
**Moderator: Margaret Thompson, MD**

**Presenters:**  
***Grassy Narrows: the Canadian Mercury Environmental Contamination, Ray Copes, MD***

***Canadian Toxicological Epidemics: McIntyre Powder - Who knew? Connie MacKenzie, MD***

At the end of the session, the participant should be able to:

1. Describe the situation in Grassy Narrows in Northern ON.
2. Understand the variable presentations of organic mercury disease.
3. Describe historical use of McIntyre Powder (inhaled aluminum powder) in the mining industry.
4. Describe the potential long-term health effects of inhaled aluminum powder.

**1:00 pm – 2:00 pm**  
**Regency Ballroom D**  
**West Tower**  
**Ballroom Level**

**PEC: Substance Misuse & Abuse: Best Practice for Reaching Tweens & Teens**  
**Moderator: Carissa McBurney, MPA**

**Presenters: Elizabeth Scharman, BS, PharmD**  
**Cristina Thomas, M.Ed, CHES**  
**Lizbeth Petty, MPH, CPH**

At the end of the session, the participant should be able to:

1. Identify the national best-practice models for substance abuse prevention.
2. Identify the part Poison Centers can play within the national best-practice models.
3. Discuss best practices for teaching substance misuse to tweens and teens.
4. Identify various substances that can be harmful if used or misused by a tween or teen.

**1:00 pm – 2:00 pm**                      **SPI: Swap and Share**  
**Crystal Ballroom A**                      **Moderators: Brooke Button, RN**  
**West Tower/Lobby Level**                      **Erin Pallasch, Pharm D**

At the end of the session, the participant should be able to:  
1. Identify 3 resources that will impact their practice.

**2:00 pm – 3:30 pm**                      **AACT Acute and Intensive Care Symposium:**  
**Regency Ballroom AB**                      **Case Studies**  
**West Tower**                      **Moderator: Bryan Hayes, PharmD**  
**Ballroom Level**                      **Jenny Lu, MD**  
**Case Studies Presenters: Elie Harmouche, MD**  
**Brian Murray, DO**  
**Ben Willenbring, MD**

**Case Studies Discussants: Timothy Erickson, MD**  
**Stephanie Hon, PharmD**  
**Daniel Rusyniak, MD**  
**Howard Greller, MD**

At the end of the session, the participant should be able to:  
1. Recognize and manage life threatening metal phosphide poisonings.  
2. Determine appropriate decontamination methods.  
3. Understand the diagnostic criteria of serotonin syndrome.  
4. Discuss the different modalities to treat serotonin syndrome.  
5. List the mechanisms of severe caffeine toxicity.  
6. Describe effective pharmacologic treatment of severe caffeine toxicity.

2:00 pm – 3:30 pm  
Regency Ballroom C  
West Tower  
Ballroom Level

**AACT Occupational/Environmental Symposium: Air quality in commercial aircraft cabins: Investigating the health implications of chemical contaminants and ventilation**  
**Moderator: David Vearrier, MD, MPH**

***Presentations:***

***Is there a toxicological explanation for features following cabin fume events? Allister Vale, MD***

***Breathing Air Supply in Commercial Aircraft Cabins: Health Implications for Passengers and Crew.***  
***Michael Kosnett, MD, MPH***

***Can analytical investigations assist in the diagnosis of cabin fume events? Col Franz Worek, MD, PhD***

At the end of the session, the participant should be able to:

1. Identify the chemicals released into cabin air and describe the features of which
2. cabin crew and passengers complain after.
3. Assess patients who complain that they have been exposed to cabin “fume events.”
4. Recognize how the commercial airline cabin is a specialized.
5. Understand the role of fresh air ventilation rate, barometric pressure, ozone and bioeffluents in affecting airline passenger and crew symptoms and comfort.
6. Discuss the pros and cons of different analytical parameters. Assess relevance of analytical results.

2:00 pm – 3:30 pm  
Regency Ballroom D  
West Tower  
Ballroom Level

**PEC Opioid Crisis: Misperceptions & Evidenced-Based Solutions**  
**Moderator: Gayle Finkelstein, RN**

***Presenters: Steve Aks, DO***  
***Elizabeth Salisbury-Afshar MD, MPH***  
***Kathie Kane Willis, MA***  
***Gabriela Zapata-Alma, LCSW, CADC***

**Bold Face** – indicates CE sessions

\* Restricted to committee members \*

\*\* Presentation will not be audio recorded\*\*

At the end of the session, the participant should be able to:

1. Describe implementing naloxone program.
2. Understand current opioid trends.
3. Understand the many misperceptions related to the opioid crisis and how misperceptions have created barriers to prevention and treatment efforts.
4. Understand how to use evidence-based practices to identify and target areas of need related to opioids.
5. Understanding the myths surrounding the opioid crisis.
6. Understand how geography impacts the types of opioids used.
7. Define harm reduction and explain its role in working with patients who use drugs.
8. Describe health-system level interventions that can be taken to promote best practices as they relate to opioid prescribing and opioid use disorder treatment.

3:30pm – 3:45 pm                      Refreshment Break  
Regency Foyer and  
Riverside East

**3:45 pm – 4:45 pm                      AACT Year in Tox Literature Review 2018:**  
**Regency Ballroom AB                      *Learn to Read Outside Our Comfort Zone***  
**West Tower                                      *Moderator: Mark Mycyk, MD***  
**Ballroom Level**  
  
***Presenters: Mark Mycyk, MD***  
***Jillian Theobald, MD, PhD***

At the end of the session, the participant should be able to:

1. Discuss recent cutting edge tox literature.
2. Identify novel solutions for emerging problems.

**3:45 pm – 4:45 pm                      APAMT Scientific Symposium: Application of**  
**Regency Ballroom C                      *Pharmacokinetic Studies***  
**West Tower                                      *Moderator: Nicholas Buckley, MD***  
**Ballroom Level**  
  
***Presenters: Angela Chiew, MBBS***  
***Geoffrey Isbister, MD***  
***Darren Roberts, MD, PhD***

**Bold Face** – indicates CE sessions

\* Restricted to committee members \*

\*\* Presentation will not be audio recorded\*\*



At the end of the session, the participant should be able to:

1. To better understand how pharmacokinetic studies in overdose may improve clinical assessment and management.
2. Understand the pharmacokinetics of snake venoms.
3. Explain how kinetics influence indications for dialysis. Understand the mechanism of antivenom and venom kinetics.

**3:45 pm – 4:45 pm**  
**Regency Ballroom D**  
**West Tower**  
**Ballroom Level**

**AAPCC SPI Best Practices: Cultivating and Encouraging a Research Environment within the Poison Center**  
**Moderator: Jamie Nisbet, RN**

**Presenters: George Layton, MD**  
**Joanne Masur, RN**

At the end of the session, the participant should be able to:

1. Propose and plan application of methods of implementing change with the PC to achieve SPI participation in research.
2. Recognize challenges and obstacles to research.
3. Identify the benefits of SPI research to the poison center and to the SPI.
4. Identify methods of implementing change within the poison center to achieve SPI participation in research.

**3:45 pm – 4:45 pm**  
**Toronto**  
**West Tower**  
**Ballroom Level**

**PEC: Partnerships with First Responders**  
**(Partnerships, Training & Outreach Opportunities)**  
**Moderator: Kristin L. Wenger, BS**

**Presenters: Britni Overall, BS**  
**Maureen Roland, RN**  
**Wendy Stephan, PhD, MPH, CHES**

At the end of the session, the participant should be able to:

1. Discuss the partnership between the Georgia Poison Center and the Cobb County Safety Village.
2. Summarize the poison safety topics that are included in the Cobb County Safety Village program.
3. Describe the collaboration between a Poison Control Center and 911 Agency.
4. Identify the process used to review a patient's medications.
5. Identify potential practical and cultural barriers to educating EMS personnel about poison center services.

4:00 pm – 4:30 pm                      Poster Session II Tear Down – Abstracts # 107-196  
 Riverside East  
 East Tower  
 Exhibit Level

4:30 pm – 5:00 pm                      Poster Session III Set Up - Abstracts # 197-286  
 Riverside East  
 East Tower  
 Exhibit Level

4:45 pm – 6:15 pm                      AAPCC Town Hall and Annual AAPCC Awards  
 Regency Ballroom C  
 West Tower  
 Ballroom Level

6:30 pm – 10:30 pm                      50<sup>th</sup> Anniversary House of Blues Dinner and Live Music  
 Offsite                                      *Sponsored by BTG*  
 (Purchased ticket required)

**Bold Face** – indicates CE sessions

\* Restricted to committee members \*

\*\* Presentation will not be audio recorded\*\*

7:00 am – 3:45 pm            NAACT Main Congress Registration / Information  
Regency Foyer  
West Tower/Ballroom Level

7:00 am – 8:30 am            Continental Breakfast  
Regency Foyer  
West Tower/Ballroom Level

7:30 am – 8:30 am            AAPCC Medical Directors  
Regency Ballroom D  
West Tower/Ballroom Level

7:30 am – 8:30 am            ACMT Fellowship Directors Committee  
Randolph 3  
East Tower/Concourse Level

7:30 am – 8:30 am            ACMT Practice Committee  
Acapulco  
West Tower  
Ballroom Level

7:30 am – 8:30 am            ACMT Clerkship Council  
Randolph 1A  
East Tower  
Concourse Level

7:30 am – 8:30 am            AACT Trainee and Student Section  
Randolph 1B  
East Tower  
Concourse Level

**Bold Face** – indicates CE sessions

\* Restricted to committee members \*

\*\* Presentation will not be audio recorded\*\*

8:30 am - 9:30 am      **\*\*AAPCC Scientific Symposium: 30 Years of Biodefense**  
**Regency Ballroom AB**      **and Emerging Infectious Diseases\*\***  
**West Tower**      **Moderator: Mark Ryan PharmD**  
**Ballroom Level**  
  
**Presenter: Edward Eitzen, MD, MPH**

At the end of the session, the participant should be able to:

1. Understand significant real-life events that have occurred in the field of Biodefense over the past 28 years.
2. Describe the current status of an investigational Ebola vaccine and where it was first used in an epidemic setting.

8:30 am – 9:30 am      **Society of Toxicology: Mitochondrial Poisoning**  
**Regency Ballroom C**      **Moderator: Ken McMartin, PhD**  
**West Tower**  
**Ballroom Level**  
  
**Presentations:**  
***Drug-Induced Myopathy through Adverse Effects on***  
***Mitochondrial Energetics, Frans G.M.Russel, PharmD, PhD***  
  
***Mitochondrial neurotherapeutics: past, present and future***  
***Ian Reynolds, PhD***

At the end of the session, the participant should be able to:

1. Understand how a systems medicine approach can be used to identify the underlying mechanism of drug-induced myopathy.
2. Explain the mitochondrial off-target effects of statins associated with muscle toxicity.
3. Understand the relationship between neuronal injury and impairment of mitochondrial function.
4. Appreciate the potential for novel therapeutics that target mitochondrial function.

8:30 am – 9:30 am      **PEC: E-cigarettes & Vaping: A Public Health Challenge**  
**Toronto**      **Moderator: Jared O'Connor, MPH, MS**  
**West Tower**  
**Ballroom Level**  
  
**Presenters: Jacqueline Kakos, MS**  
**Atri Patel, CHES**

**Bold Face** – indicates CE sessions

\* Restricted to committee members \*

\*\* Presentation will not be audio recorded\*\*

At the end of the session, the participant should be able to:

1. Identify the difference between open and closed systems.
2. Understand how differences in e - cig anatomy inform state - level legislation.
3. Understand the factors that contribute to the social acceptance of vaping.
4. Identifying the dangers of using vaping devices.

9:30 am – 2:45 pm                      Exhibits/ Poster Session III - Abstracts # 197-286  
Riverside East  
East Tower  
Exhibit Level

9:30 am – 10:30 am                      Authors with Posters / Abstracts # 197-286  
Riverside East                              Refreshment Break  
East Tower  
Exhibit Level

**10:30 am – 11:30 am                      AACT Debate: THC - Friend or Foe**  
**Regency Ballroom AB                      *Moderator: Jennifer Lowry, MD***  
**West Tower**  
**Ballroom Level                              *Presenters: Jerrold Leiken, MD***  
***Leslie Meddonza Temple, MD, ABOIM***

At the end of the session, the participant should be able to:

1. Consider the advantages and disadvantages of delta-9 tetrahydrocannabinol (THC) in clinical use.
2. Learn about advantages and pitfalls in the clinical use of medical cannabis from an early adopter clinician in Illinois.
3. Learn about perspectives on medical cannabis use from a toxicologist's perspective.

10:30 am – 11:00 am      **Lightning Oral Abstracts: # 36, 37, 205, 206**  
Regency Ballroom C      **Moderator: Kirk Cumpston, DO**  
West Tower  
Ballroom Level

**#36 Studies with enucleated rabbit eyes exposed topically to 10% phenol and decontaminated with amphoteric solutions or tap water: EVEIT and OCT findings, Alan Hall, MD**

**#37 Shaken not Stirred, An Assessment of Residual Charcoal after Administration, Brett Cherrington, MD**

**#205 Impact of healthcare resources on intentional and unintentional toxic exposures in urban and rural communities, Paulius Mui, BA, Eleanor Love, BS**

**#206 Utilizing a Poison Center Electronic Medical Record to Facilitate Real-time Studies Robert Geller, MD**

At the end of the session, the participant should be able to:

1. Understand the research methods employed in this study: EVEIT (Ex Vivo Eye Irritation Test) and OCT (Optical Coherence Tomography) and their uses.
2. Explain the differences found in this study between results of eye decontamination with tap water and two amphoteric solutions.
3. Discuss administration techniques for activated charcoal.
4. Discuss some reasons why complete dose of activated charcoal is not always given.
5. Compare and contrast the different trends in toxic exposures in urban versus rural communities.
6. List how differences in availability of healthcare resources impacts intentionality and outcome of toxic exposures.
7. Discuss 3 benefits from using direct data collection within an EMR for studies.
8. Discuss 3 requirements to be able to extract the collected data.

**Bold Face** – indicates CE sessions

\* Restricted to committee members \*

\*\* Presentation will not be audio recorded\*\*

10:30 am – 11:30 am      **PEC: HRSA (Health Resources and Services Administration) Updates**  
 Toronto  
 West Tower                      **Moderator: Kristin Wenger BS, MA Teaching**

**Presenter: Jeremy Nelson**

At the end of the session, the participant should be able to:

1. Understand Poison Program activities.

11:00 am – 11:30 am      **AACT Tox History Special Interest Symposium Section: Chicago Tox History**  
 Regency Ballroom C  
 West Tower                      **Moderator: Anna Arroyo Plasencia, MD**  
 Ballroom Level

**Presenters: Frank Paloucek, BS Pharm, PharmD  
 Carol DesLauriers, PharmD**

At the end of the session, the participant should be able to:

- 1 Describe Chicago poisonings of historical significance.
2. Identify changes in clinical practice or public health that came about as a result of a toxicology incident that occurred in Chicago.

11:30 am – 12:30 pm      Lunch on Your Own

11:30 am - 12:30 pm      ACMT Addiction Medicine Section  
 Randolph 3  
 East Tower  
 Concourse Level

11:30am – 12:30 pm      ACMT Government Section  
 Acapulco  
 West Tower  
 Ballroom Level

11:30 am – 12:30 pm      ACMT Industry Section  
 Randolph 1A  
 East Tower  
 Concourse Level

**Bold Face** – indicates CE sessions

\* Restricted to committee members \*

\*\* Presentation will not be audio recorded\*\*

11:30 am – 12:30 pm      AAPCC Public Health Committee  
Randolph 1B  
East Tower  
Concourse Level

11:30 am – 12:30 pm      PEC 2019 NACCT Planning Meeting  
Roosevelt 3AB  
East Tower  
Concourse Level

**12:30 pm – 1:30 pm      Platform Session III: Abstracts #13 - 16**  
**Regency Ballroom AB      Moderators: Jeanna Marraffa, PharmD**  
**West Tower                      Shawn Varney, MD**  
**Ballroom Level**

**#13 Serious Loperamide Exposures and Cardiotoxicity, 2000-2017,**  
*Jenna Marraffa, PharmD*

**#14 Outbreak of Coagulopathy Associated with Synthetic Cannabinoid Use,**  
*Jason Devgun, MD*

**#15 Bystander naloxone administration for undifferentiated opioid overdose in the era of non-pharmaceutical fentanyl: a retrospective study of a regional poison center data,** *Sarah Mahonski, MD*

**#16 Comparison Of Pediatric Buprenorphine And Methadone Exposures Reported To The U.S. Poison Centers, 2013 – 2016,** *Saumitra Rege, PhD*

At the end of the session, the participant should be able to:

- 1 Describe the serious cardiotoxicity secondary to loperamide exposures compared to other opioids reported to Poison Centers.
- 2 Identify contaminants in drugs of abuse as a cause of toxicity.
- 3 Understand mechanism of toxicity for coumarin rodenticides.
- 4 Understand the impact of non-pharmaceutical fentanyl on naloxone dosing in undifferentiated opioid overdose.
- 5 Comparing the Trends and Characteristics of Pediatric Buprenorphine and Methadone exposures reported to the US Poison Centers.

**Bold Face** – indicates CE sessions

\* Restricted to committee members \*

\*\* Presentation will not be audio recorded\*\*



**12:30 pm – 2:00 pm**  
**Regency Ballroom C**  
**West Tower**  
**Ballroom Level**

**AACT Pediatric Special Interest Section/ACMT Pediatric Section Symposium: Child Maltreatment & Toxicology**  
**Moderator: Christine Murphy, MD**

**Presenters: Michele Burns, MD**  
**Christine Murphy, MD**

**Panelists: Veena Ramaiah, MD**  
**Shan Yin, MD**  
**Katherine O'Donnell, MD**  
**Jennifer Lowry, MD**  
**Michele Burns, MD**

At the end of the session, the participant should be able to:

- 1 Identify red flags or indications of the trafficked patient.
- 2 Develop treatment plans for withdrawal of the trafficked patient.
- 3 Identify clinical scenarios when child abuse by poisoning should be suspected.
- 4 Discuss laboratory testing which may aid in the diagnosis of child maltreatment by poisoning.

**12:30 pm – 2:00 pm**  
**Regency Ballroom D**  
**West Tower**  
**Ballroom Level**

**PEC: Marijuana: Public Health, Health Policy and Law**  
**Moderator: Gayle Finkelstein, RN**

**Presenter: Leslie Meddonza Temple, MD, ABOIM**  
**Panelists: Michael Fine, JD**  
**Rep. Lou Lang, JD**  
**Joseph Friedman, RPh**

At the end of the session, the participant should be able to:

1. Perspectives on the opioid crisis and treating plan.
2. Health benefits and risks of medical cannabis.
3. The use of medical cannabis as an alternative or adjunct to opioids, benzodiazepines, nonopioid pain medications.
4. Updates on legislation: Examine the relationship between health policy, public health and law regarding the use of cannabis.
5. Perspectives from the medical cannabis industry-a pharmacist's viewpoint.
6. Patient advocacy.

**Bold Face** – indicates CE sessions

\* Restricted to committee members \*

\*\* Presentation will not be audio recorded\*\*

**1:30 pm – 2:30 pm**      ***Response to Synthetic Cannabinoids and LAARs in Illinois***  
**Regency Ballroom AB**      ***Moderator: Steve Aks DO***  
**West Tower**  
**Ballroom Level**      ***Panelists: Michael Wahl, MD***  
      ***Jennifer Layden, MD, PhD***  
      ***Luke Yip, MD***  
      ***Jason Devgun, MD***  
      ***Robert Middleberg, PhD***

At the end of the session, the participant should be able to:

1. Understand the working of public health, toxicologists and poison control.
2. Understand the role of the medical toxicologist during an outbreak.

**1:30 pm – 2:30 pm**      **ACMT Visiting Professor's Lecture:**  
**Toronto**      ***Pursuing A Research Career As A Medical Toxicology***  
**West Tower**      ***Fellow: The Good, The Bad And The Ugly***  
**Ballroom Level**      ***Moderator: Navneet Cheema, MD***  
  
      ***Presenters: David Jang, MD, MSc***  
      ***Stephanie Carreiro, MD***

At the end of the session, the participant should be able to:

1. To learn about opportunities for medical toxicology fellows to pursue a research career.
2. To learn various strategies to be successful: identify an appropriate mentor (s), generating publications, developing an innovative research plan, and finding a supportive environment.

**2:30 pm – 2:45 pm**      **Refreshment Break**  
**Regency Foyer and**  
**Riverside East**

**Bold Face** – indicates CE sessions

\* Restricted to committee members \*

\*\* Presentation will not be audio recorded\*\*

**2:45 pm – 3:45 pm**                      **Toxicological Jeopardy for SPIs**  
**Regency Ballroom D**                      ***Moderator: Edward Bottei, MD***  
**West Tower**  
**Ballroom Level**

At the end of the session, the participant should be able to:

1. Identify diagnostic clues to help recognize uncommon exposures.
2. List diagnostic criteria for certain common exposures or syndromes.
3. Discuss strategies for managing uncommon exposures.

**2:45 pm - 3:45 pm**                      **AACT Sports Special Interest Section Symposium: 50**  
**Regency Ballroom AB**                      ***Years of Performance Enhancing Drugs***  
**West Tower**                                      ***Moderator/Presenter: Christopher Hoyte, MD***  
**Ballroom Level**

At the end of the session, the participant should be able to:

1. Be able to identify cases where athletic performance enhancing drugs used in the last 50 years.
2. Discuss the next frontier in athletic performance enhancing drugs.

**2:45 pm – 3:45 pm**                      **PEC: Online Tools for Health Information (Helpline Chat &**  
**Toronto**    ***Text Tools, Online Training and Education for both the***  
**West Tower**    ***general public & healthcare professionals)***  
**Ballroom Level**    ***Moderator: Carissa McBurney, MPA***

***Presenters: Vickie Dance, MS***  
***Britni Overall, BS, CHES***

At the end of the session, the participant should be able to:

1. Identify at least 2 new online health information tools or methods to integrate into your programs, services, campaigns and/or resources.
2. Discuss the online poison prevention training program.
3. Summarize the poison safety topics that are included in the online poison prevention training program.

2:45 pm – 3:45 pm      AACT Fellows-in-Training Oral Platform Session  
 Regency Ballroom C      *Moderator: Kennon Heard, MD*  
 West Tower  
 Ballroom Level

**#104 Graft Failure Rates of Opioid Overdose Donors Compared to Other Drug Overdose Donors, Theresa Kim, MD**

**#135 Lack of seizures in patients presenting to the ED with suspect benzodiazepine toxicity reversed by flumazenil, Eric McGillis, MD**

**#192 The Risk of Seizure After Naloxone Administration in Tramadol Exposures, Musa Alfaifi, MD**

**#197 *\*\*Patterns of repeat self-poisoning based on a novel poison center,\*\** Jonathan Schimmel, MD**

At the end of the session, the participant should be able to:

1. Compare graft failure rates in patients who died of overdose from opioids to overdose from other drugs.
2. Describe the use of organs procured from patients who died of opioid related causes.
3. Describe the rate of seizures in an emergency department population receiving flumazenil for suspected benzodiazepine overdose.
4. Outline the contraindications commonly suggested for use of flumazenil in the emergency department.
5. Naloxone administration in tramadol exposures was not associated with the occurrence of seizures after adjustment for confounding variables as reported to NPDS during a 10-year period.
6. Describe prior literature on patterns of repeat self-harm attempts.
7. Describe patterns of repeat self-poisoning found in this study.

2:45 pm –3:30 pm      Poster Session III Tear Down – Abstracts # 197-286  
 Riverside West  
 East Tower  
 Exhibit Level

4:00 pm – 6:00 pm      Chicago Gangland Tour  
 Offsite      (Purchased Ticket Required)

**Bold Face** – indicates CE sessions

Page 44 of 45

\* Restricted to committee members \*

\*\* Presentation will not be audio recorded\*\*

8:00 am – 1:00 pm      \*AAPCC Board Meeting (Part 2)\*  
Randolph 1AB  
East Tower  
Concourse Level

**Bold Face** – indicates CE sessions

\* Restricted to committee members \*

\*\* Presentation will not be audio recorded\*\*